| Trial ID: | L5980 |
| Source ID: | NCT00571506
|
| Associated Drug: |
Rosiglitazone
|
| Title: |
Effect of Thiazolidinedione Treatment Vascular Risk Markers
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2|Vascular Diseases
|
| Interventions: |
DRUG: Rosiglitazone|DRUG: Pioglitazone
|
| Outcome Measures: |
Primary: determine if treatment with rosiglitazone or pioglitazone affects platelet function as assessed by spontaneous and agonist-induced platelet aggregation, 3 months | Secondary: adipocytokine concentrations (adiponectin, leptin), hemostatic parameters (fibrinogen, plasminogen activator inhibitor-1), high-sensitivity C-reactive protein, 3 months
|
| Sponsor/Collaborators: |
Sponsor: University of Arkansas
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
25
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2004-05
|
| Completion Date: |
2007-08
|
| Results First Posted: |
|
| Last Update Posted: |
2009-12-09
|
| Locations: |
University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00571506
|
